Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Janelle Dempsey

Goodwin Procter

main

Dempsey Janelle

Goodwin Associate Janelle Dempsey, from Boston, practices in the Litigation Department with an emphasis on complex litigation and dispute resolution.

Janelle Dempsey

Areas of Practice

Credentials

Education

JD

Bachelor of Arts

Admissions

Bars

Related Content

Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics’ PEG Supply Business and Manufacturing Facility

Novo Holdings to Acquire Catalent in All-Cash $16.5 Billion Transaction

Harpoon Therapeutics To Be Acquired by Merck for $680 Million

Manta Software Acquired By IBM

KBP Biosciences Announces Sale of Ocedurenone to Novo Nordisk for up to $1.3 Billion

Bev Acquired by E. & J. Gallo Winery

Subject Matter and Kivvit Combine to Create National Communications and Advocacy Powerhouse

TCR² Therapeutics and Adaptimmune Enter Into Strategic Combination To Create A Preeminent Cell Therapy Company For Solid Tumors

Complex Litigation & Dispute Resolution

Employment

Janelle Dempsey

Areas of Practice

Credentials

Education

JD

Bachelor of Arts

Admissions

Bars

Related Content

Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics’ PEG Supply Business and Manufacturing Facility

Novo Holdings to Acquire Catalent in All-Cash $16.5 Billion Transaction

Harpoon Therapeutics To Be Acquired by Merck for $680 Million

Manta Software Acquired By IBM

KBP Biosciences Announces Sale of Ocedurenone to Novo Nordisk for up to $1.3 Billion

Bev Acquired by E. & J. Gallo Winery

Subject Matter and Kivvit Combine to Create National Communications and Advocacy Powerhouse

TCR2 Therapeutics and Adaptimmune Enter Into Strategic Combination To Create A Preeminent Cell Therapy Company For Solid Tumors

TCR² Therapeutics and Adaptimmune Enter Into Strategic Combination To Create A Preeminent Cell Therapy Company For Solid Tumors